In the context of translating preclinical findings into clinical therapies for RA, considerable attention has been drawn to pharmacological modulators of the PI3K/AKT/mTOR cascade that impact the functional profile of RA-FLSs. The gene discussed is MTOR; the disease is rheumatoid arthritis.